For this reason, much of our evidence is based on CV risk reduction and does not require lipid levels for inclusion criteria. This CPG addresses the various treatment and management strategies for managing lipids among patients at risk for CVD morbidity and mortality focusing upon an individual s risk factors and event history. III. About this Clinical Practice Guideline This guideline is aimed at efficiently improving dyslipidemia management for CV risk reduction in the VA and DoD. It is intended for use by all VA and DoD healthcare providers. This CPG is not intended to serve as a standard of care. Standards of care are determined on the basis of all clinical data available for an individual patient and are subject to change as scientific knowledge and technology advance and patterns evolve. This CPG is based on information available on or before May 16, 2019, and is intended to provide general guidance to the best evidence-based practices (see Appendix A for additional information on the evidence review methodology). While this guideline can assist providers, a CPG s content must always be considered as a recommendation, within the context of a provider s clinical judgment and patient values and preferences. The evolution of medical practice and future scientific research will likely impact these recommendations. After assessing the currently available evidence, the Work Group determined future research topics, which are outlined in applicable discussion sections. An abbreviated provider summary, patient summary, and pocket card are available at this link: https://www.healthquality.va.gov/guidelines/CD/lipids/. A. Methods This document is an update to the 2014 VA/DoD Dyslipidemia CPG. The methodology used in developing the 2020 CPG follows the Guideline for Guidelines, a VA and DoD EBPWG document that was updated in January 2019.[4] The Guideline for Guidelines can be downloaded from http://www.healthquality.va.gov/policy/index.asp. 